ArticleCancer gene therapy2009
High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome.
Article in Cancer gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Neoadjuvant personalized viral vaccine prevents tumor relapse in checkpoint-resistant murine melanoma model.Journal for immunotherapy of cancer · 2025Article
- PD-L1 antibody enhanced β-glucan antitumor effects via blockade of the immune checkpoints in a melanoma model.Cancer immunology, immunotherapy : CII · 2023Article
- Oncolytic virus and PD-1/PD-L1 blockade combination therapy.Oncolytic virotherapy · 2018Review
- Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor GrowthFrontiers in pharmacology · 2016Article
- Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines.Frontiers in oncology · 2014Review
- Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis.Critical reviews in oncology/hematology · 2013Review
- Article
- Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy.Frontiers in oncology · 2012Article
- Targeting T cells with bispecific antibodies for cancer therapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2011Review
- Engineering dendritic cells to enhance cancer immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Review
- Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Potentiating cancer immunotherapy using an oncolytic virus.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responses.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- DNA vaccination: using the patient's immune system to overcome cancer.Clinical & developmental immunology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have investigated the therapeutic potential of a prototypic melanoma vaccine based on recombinant adenovirus expressing human dopachrome tautomerase in the B16F10 murine melanoma model. We found that in the presence of a tumor, the magnitude of T-cell immunity evoked by the vaccine was significantly reduced. This impairment was compounded by defects in cytokine production and degranulation within the tumor-infiltrating lymphocytes (TILs). We showed that the combination of vaccination with high-dose cyclophosphamide was able to skew the response toward the target antigen and enhanced both the quantity and quality of antigen-specific CD8+ and CD4+ T-cell responses in tumor-bearing mice, which resulted in the inhibition of tumor growth. Furthermore, when tumor-specific antigens were targeted by the vaccine, the combination therapy could actually produce tumor regression, which appeared to result from the high frequency of antigen-specific T cells. These data show that recombinant adenovirus vaccines are compatible with conventional high-dose chemotherapy and that the combined treatment results in improved therapeutic outcomes relative to either agent individually.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.